Krishnan Krish S sold $53K of KRYS
Krishnan Krish S (President and CEO) sold 176 shares of Krystal Biotech, Inc. (KRYS) at $303.17 on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing confirms an officer/director/10% owner open-market sale executed under a pre-arranged 10b5-1 plan; it is not evidence of a new fundamental development by itself.
Market read
Provides a fresh insider-selling datapoint for KRYS, but 10b5-1 labeling suggests limited incremental trading signal.
What to watch
Traders should check whether the company has concurrent insider buys/sales or upcoming catalysts; this filing alone may not explain price moves.
Background
This is an SEC Form 4 insider transaction disclosure for Krystal Biotech (KRYS).
Ticker impact
Krystal Biotech CEO/10% owner sold 176 shares in an open-market transaction at ~$303.17 under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any reaction should be muted unless accompanied by other fundamental news.
Form 4 provides a specific sale datapoint, yet it is explicitly tied to a pre-arranged 10b5-1 plan, which typically dampens interpretive value.
Market effects
Minimal—single-company insider transaction with no stated operational/regulatory catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is small relative to holdings and executed under 10b5-1, it may reflect routine liquidity rather than negative expectations.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderKrishnan Krish S
President and CEO; sold 176 shares under a 10b5-1 plan.
